Compare Stocks: INKT, FTFT, ANIK, and IFRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$19.23 -1.5%	$20.66	$8.67 ▼ $22.88	$257.30M	0.21	113,209 shs	126,202 shs
FTFT Future FinTech Group	$3.37 +5.0%	$3.41	$1.22 ▼ $152.96	$31.61M	1.7	1.73 million shs	49,635 shs
IFRX InflaRx	$1.53 -1.9%	$2.00	$0.80 ▼ $2.95	$225.48M	2.59	1.07 million shs	1.14 million shs
INKT MiNK Therapeutics	$11.00 -3.7%	$11.63	$8.48 ▼ $16.93	$56.10M	0.47	111,066 shs	10,259 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	+2.14%	-0.66%	-6.15%	+21.38%	+114.85%
FTFT Future FinTech Group	-5.31%	-5.59%	+96.93%	-58.20%	-97.84%
IFRX InflaRx	-1.27%	-13.33%	-29.73%	-24.27%	+13.04%
INKT MiNK Therapeutics	-2.39%	-9.00%	-1.89%	-0.35%	-23.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$19.23 -1.5%	$20.66	$8.67 ▼ $22.88	$257.30M	0.21	113,209 shs	126,202 shs
FTFT Future FinTech Group	$3.37 +5.0%	$3.41	$1.22 ▼ $152.96	$31.61M	1.7	1.73 million shs	49,635 shs
IFRX InflaRx	$1.53 -1.9%	$2.00	$0.80 ▼ $2.95	$225.48M	2.59	1.07 million shs	1.14 million shs
INKT MiNK Therapeutics	$11.00 -3.7%	$11.63	$8.48 ▼ $16.93	$56.10M	0.47	111,066 shs	10,259 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	+2.14%	-0.66%	-6.15%	+21.38%	+114.85%
FTFT Future FinTech Group	-5.31%	-5.59%	+96.93%	-58.20%	-97.84%
IFRX InflaRx	-1.27%	-13.33%	-29.73%	-24.27%	+13.04%
INKT MiNK Therapeutics	-2.39%	-9.00%	-1.89%	-0.35%	-23.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIK Anika Therapeutics	2.25	Hold	$22.00	14.40% Upside
FTFT Future FinTech Group	1.00	Sell	N/A	N/A
IFRX InflaRx	2.67	Moderate Buy	$7.43	385.53% Upside
INKT MiNK Therapeutics	2.00	Hold	$35.00	218.18% Upside

Current Analyst Ratings Breakdown

Latest INKT, FTFT, ANIK, and IFRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/28/2026	ANIK Anika Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/21/2026	ANIK Anika Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	FTFT Future FinTech Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/21/2026	IFRX InflaRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	ANIK Anika Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$21.00 ➝ $23.00
9/14/2026	IFRX InflaRx	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/5/2026	ANIK Anika Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIK Anika Therapeutics	$112.82M	2.28	N/A	N/A	$9.95 per share	1.93
FTFT Future FinTech Group	$3.83M	8.25	N/A	N/A	$139.32 per share	0.02
IFRX InflaRx	$30K	7,515.87	N/A	N/A	$0.65 per share	2.35
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($3.03) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIK Anika Therapeutics	-$10.88M	-$0.27	N/A	66.31	13.66	-3.14%	0.20%	0.15%	11/4/2026 (Estimated)
FTFT Future FinTech Group	-$4.62M	-$30.16	N/A	N/A	N/A	-157.53%	-12.22%	-10.08%	N/A
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
INKT MiNK Therapeutics	-$12.49M	-$2.40	N/A	N/A	N/A	N/A	N/A	-92.37%	11/12/2026 (Estimated)

Latest INKT, FTFT, ANIK, and IFRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	ANIK Anika Therapeutics	$0.42	N/A	N/A	N/A	$29.44 million	N/A
8/14/2026	Q2 2026	FTFT Future FinTech Group	N/A	-$5.04	N/A	-$1.26	N/A	$0.33 million
8/13/2026	Q2 2026	INKT MiNK Therapeutics	-$0.60	-$0.62	-$0.02	-$0.62	N/A	N/A
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
7/29/2026	Q2 2026	ANIK Anika Therapeutics	$0.03	$0.42	+$0.39	$0.24	$29.21 million	$32.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIK Anika Therapeutics	N/A	N/A	N/A	N/A	N/A
FTFT Future FinTech Group	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIK Anika Therapeutics	N/A	4.48	3.19
FTFT Future FinTech Group	N/A	6.71	6.71
IFRX InflaRx	N/A	8.22	8.22
INKT MiNK Therapeutics	N/A	1.23	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIK Anika Therapeutics	91.53%
FTFT Future FinTech Group	0.19%
IFRX InflaRx	42.39%
INKT MiNK Therapeutics	2.87%

Insider Ownership

Company	Insider Ownership
ANIK Anika Therapeutics	12.08%
FTFT Future FinTech Group	1.50%
IFRX InflaRx	16.30%
INKT MiNK Therapeutics	20.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIK Anika Therapeutics	235	13.38 million	11.77 million	Optionable
FTFT Future FinTech Group	32	9.38 million	9.23 million	No Data
IFRX InflaRx	65	147.37 million	123.35 million	Optionable
INKT MiNK Therapeutics	15	5.10 million	4.06 million	No Data

INKT, FTFT, ANIK, and IFRX Headlines

Recent News About These Companies

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

October 2, 2026 | globenewswire.com

Mink Therapeutics, Inc. Announces Selection of Clinical-Stage Agent-797 Inkt Platform for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy

October 1, 2026 | marketscreener.comM

MiNK Therapeutics (NASDAQ:INKT) Shares Up 2.4% - Still a Buy?

October 1, 2026 | americanbankingnews.com

MiNK Selected For ARPA-H Program To Advance Room-Temperature Cell Therapy

September 30, 2026 | rttnews.com

MiNK Therapeutics’ agenT-797 Selected for ARPA-H BoSS Program to Advance Room-Temperature Cell Therapy Storage

September 30, 2026 | quiverquant.comQ

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

September 30, 2026 | globenewswire.com

MiNK Therapeutics (NASDAQ:INKT) Shares Down 1.6% - Time to Sell?

September 9, 2026 | marketbeat.com

MiNK outlines 4-8 patients per site per month as U.S. ARDS enrollment starts in September

August 14, 2026 | seekingalpha.com

MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...

August 14, 2026 | uk.finance.yahoo.com

MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary

August 14, 2026 | finance.yahoo.com

MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript

August 14, 2026 | benzinga.com

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

August 13, 2026 | globenewswire.com

MiNK Therapeutics Inc.

August 10, 2026 | marketwatch.com

MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia

August 6, 2026 | blockonomi.com

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

August 6, 2026 | markets.businessinsider.com

MiNK Therapeutics to Report Second Quarter 2026 Financial Results and Provide Corporate Update on agenT-797 Clinical Progress

August 6, 2026 | quiverquant.comQ

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

August 6, 2026 | globenewswire.com

Here's Why You Should Add INKT Stock to Your Portfolio Now

July 16, 2026 | zacks.com

Insider Selling: MiNK Therapeutics (NASDAQ:INKT) Director Sells 1,500 Shares of Stock

June 6, 2026 | insidertrades.com

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

June 3, 2026 | globenewswire.com

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

May 28, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, ANIK, and IFRX Company Descriptions

Anika Therapeutics NASDAQ:ANIK

$19.23 -0.30 (-1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$19.24 +0.00 (+0.03%)

As of 04:15 PM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Future FinTech Group NASDAQ:FTFT

$3.37 +0.16 (+4.98%)

As of 04:00 PM Eastern

Future FinTech Group Inc., through its subsidiaries, operates online shopping platforms in People's Republic of China. It operates in three segments: Supply Chain Financing Service and Trading Business, Asset Management Service, and Others. The company offers cross-border money transfer service, brokerage and investment banking, and cryptocurrency mining farm business. It also engages in the trading of coal, aluminum ingots, sand, and steel; and E-commerce, digital wallet safety management, blockchain code auditing and operations, cryptocurrency mining, metaverse and big data maintenance services. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in New York, New York.

InflaRx NASDAQ:IFRX

$1.53 -0.03 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 +0.00 (+0.33%)

As of 04:34 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

MiNK Therapeutics NASDAQ:INKT

$11.00 -0.42 (-3.68%)

Closing price 03:59 PM Eastern

Extended Trading

$11.30 +0.30 (+2.72%)

As of 06:00 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INKT, FTFT, ANIK, and IFRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INKT, FTFT, ANIK, and IFRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INKT, FTFT, ANIK, and IFRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, ANIK, and IFRX Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Future FinTech Group NASDAQ:FTFT

InflaRx NASDAQ:IFRX

MiNK Therapeutics NASDAQ:INKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INKT, FTFT, ANIK, and IFRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INKT, FTFT, ANIK, and IFRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INKT, FTFT, ANIK, and IFRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, ANIK, and IFRX Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Future FinTech Group NASDAQ:FTFT

InflaRx NASDAQ:IFRX

MiNK Therapeutics NASDAQ:INKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools